Spero stock. Spero Therapeutics stock was originally listed at a price of $11. These guidelines expand the scope of prior UTI guidelines to address complicated UTI, provide a clinically-relevant classification of Historical daily share price chart and data for Spero Therapeutics since 2017 adjusted for splits and dividends. Dreamstime is the world`s largest stock photography community. Access forecasts, historical data, and expert insights to inform your investment decisions. Feb 13, 2026 · Get Spero Therapeutics Inc (SPRO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. (SPRO) stock, including real-time price, chart, key statistics, news, and more. (SPRO) stock quote, history, news and other vital information to help you with your stock trading and investing. 60%, respectively, for the quarter ended March 2025. Stay ahead with Nasdaq. co/fees for details. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Research Spero Therapeutics' (Nasdaq:SPRO) fundamentals, past performance, valuation, dividends and more. Research Spero Therapeutics' (Nasdaq:SPRO) fundamentals, past performance, valuation, dividends and more. View live Spero Therapeutics, Inc. Get the latest Spero Therapeutics, Inc SPRO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. 雪球为您提供Spero Therapeutics (SPRO)股票实时行情,资金流向,新闻资讯,研究报告,社区互动,交易信息,个股点评,公告,财务指标分析等与Spero Therapeutics (SPRO)股票相关的信息与服务. The latest closing stock price for Spero Therapeutics as of January 20, 2026 is 2. Real time Spero Therapeutics (SPRO) stock price quote, stock graph, news & analysis. (SPRO) stock. View today's Spero Therapeutics Inc stock price and latest SPRO news and analysis. Access financial reports, stock info, press releases, and more for informed investment decisions. Spero Therapeutics, Inc. chart to track its stock's price action. Read more here. SPRO | Complete Spero Therapeutics Inc. Shares of Spero Therapeutics SPRO more than tripled in market value yesterday after a phase III study evaluating its investigational oral antibiotic for complicated urinary tract infections (cUTIs Find the latest Spero Therapeutics, Inc. In Stock SPERO Studio 1/12 Scale Animal Kingdom Head Carving Pack Weapon Pack 6-inch Doll Accessories Model DIY US $17. With Spero Therapeutics stock trading at $2. 4 days ago · See the latest Spero Therapeutics Inc stock price (SPRO:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Learn why top analysts are making this stock forecast for Spero Therapeutics at MarketBeat. Find market predictions, SPRO financials and market news. 38. 00. . Get the latest Spero Therapeutics Inc (SPRO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 50 in Nov 2 SPRO's current price target is $0. Discover historical prices for SPRO stock on Yahoo Finance. View the real-time Spero Therapeutics Inc (NASDAQ SPRO) share price. (SPRO), analyze all the data with a huge range of indicators. Looking to buy Spero Therapeutics Stock? Get the latest SPRO quote, news, earnings, forecast, price targets, and market insights. , a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. | Nasdaq: SPRO | Nasdaq You can buy and sell Spero Therapeutics (SPRO) and other stocks, ETFs, and their options commission-free on Robinhood with real-time quotes, market data, and relevant news. Tebipenem's approval in 2026 under SPA could bring Spero $400M+ in milestones & royalties. View daily, weekly or monthly format back to when Spero Therapeutics, Inc. Find the latest Spero Therapeutics, Inc. The all-time high Spero Therapeutics stock closing price was 22. Learn how to buy Spero Therapeutics stock securely on Kraken. 2 days ago · Should You Buy or Sell Spero Therapeutics Stock? Get The Latest SPRO Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. (SPRO) stock at Seeking Alpha. 3 days ago · A detailed overview of Spero Therapeutics, Inc. GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U. Stock forecasts and analyst price target predictions for Spero Therapeutics, Inc. 07 on December 28, 2020. How much is Spero Therapeutics stock worth today? (NASDAQ: SPRO) Spero Therapeutics currently has 56,339,295 outstanding shares. View Spero Therapeutics, Inc SPRO investment & stock information. (SPRO) stock news and headlines to help you in your trading and investing decisions. Create real-time notifications to follow any changes in the live stock price. View (SPRO) real-time stock price, chart, news, analysis, analyst reviews and more. Get Spero Therapeutics Inc (SPRO. 39 per share, the total value of Spero Therapeutics stock (market capitalization) is $134. Get the latest news and real-time alerts from Spero Therapeutics, Inc. com -- Spero Therapeutics (NASDAQ:SPRO) stock rose 7% on Tuesday after the company and partner GSK (NYSE:GSK) announced positive Phase 3 trial results for tebipenem HBr, a potential Interactive Chart for Spero Therapeutics, Inc. News. Download Spero Dentist stock photos. Get Spero Therapeutics Inc (SPRO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Spero Therapeutics’ oral antibiotic tebipenem shows Phase 3 success and supports GSK’s NDA resubmission. Spero Therapeutics (SPRO) delivered earnings and revenue surprises of 54. 91 -47% SPRO - Spero Therapeutics Inc - Stock screener for investors and traders, financial visualizations. SPRO Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Spero Therapeutics Inc. (NASDAQ:SPRO) saw its stock soar by 240% after announcing highly encouraging results from its Phase 3 PIVOT-PO trial, conducted in collaboration with development partner Spero Therapeutics (SPRO) stock price, charts, trades & the US's most popular discussion forums. Two former executives from Spero Therapeutics have agreed to settle with the Securities and Exchange Commission (SEC) for allegedly misleading investors about the efficacy of the biotech’s lead Spero Therapeutics, Inc. 44 US $32. Highlights of Recent Developments: The exciting phase 3 trial results of tebipenem HBr, a joint development between Spero Therapeutics and GSK, have successfully met the primary endpoint. Should You Buy or Sell Spero Therapeutics Stock? Get The Latest SPRO Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Click here to read my latest analysis of SPRO stock. View real-time SPRO stock price and news, along with industry-best analysis. A high-level overview of Spero Therapeutics, Inc. Get real-time Spero Therapeutics (SPRO) stock price, charts, news, and analyst ratings on Benzinga. stock information by Barron's. 15 percent due to promising trial results and FDA approval. Spero Therapeutics (SPRO) stock jumps as GSK (GSK) partnered oral UTI treatment, tebipenem HBr, succeeds in a pivotal Phase 3 trial. stock news by MarketWatch. (SPRO) stock price, news, historical charts, analyst ratings and financial information from WSJ. Should I buy Spero Therapeutics (SPRO)? Use the Zacks Rank and Style Scores to find out is SPRO is right for your portfolio. S. Do the numbers hold clues to what lies ahead for the stock? The latest Spero Therapeutics stock prices, stock quotes, news, and SPRO history to help you invest and trade smarter. stock was issued. (SPRO) stock, with detailed revenue and earnings estimates. View real-time stock prices and stock quotes for a full financial overview. Investing. Assess historical data, charts, technical analysis and contribute in the forum. Free forex prices, toplists, indices and lots more. This achievement catapulted Spero’s shares by more than 230% […] Under this agreement GSK has sub-licensed back to Spero Therapeutics the rights and responsibility to conduct certain development work including the PIVOT-PO Phase 3 trial, after which sponsorship of the new drug application (NDA) will be transferred to GSK from Spero Therapeutics. Common Stock (SPRO) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. These guidelines provide practical advice for clinicians who manage patients with cUTIs in inpatient and outpatient settings. Free or royalty-free photos and images. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. com. Read more on why SPRO is a Buy, given acquisition interest and other upside potential. Get real-time Spero Therapeutics Inc (SPRO) stock price, news, financials, community insights, and trading ideas. 總覽Biotechnology / Healthcare Spero Therapeutics, Inc. Start investing on Public. Find the latest Spero Therapeutics, Inc. Get the latest Spero Therapeutics, Inc. View the latest Spero Therapeutics Inc. Check if SPRO Stock has a Buy or Sell Evaluation. Discover real-time Spero Therapeutics, Inc. MSN Spero Therapeutics Inc. Use them in commercial designs under lifetime, perpetual & worldwide rights. ’s stocks have been trading up by 13. GSK is riding to the rescue of Spero Therapeutics’ oral antibiotic prospect, paying $66 million upfront for near-global rights to a drug candidate that needs to undergo another phase 3 trial Track Spero Therapeutics (SPRO) stock price, view market trends and access key financial insights. Interactive Chart for Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock soar by 240% after announcing highly encouraging results from its Phase 3 PIVOT-PO trial, conducted in collaboration with development partner July 17, 2025 IDSA has released the first IDSA guidelines on management and treatment of complicated urinary tract infections (cUTIs). (SPRO:NASDAQ): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Spero Therapeutics, Inc. 55% and 46. 65M. Other Robinhood Financial fees may apply, check rbnhd. Feb 13, 2026 · Complete Spero Therapeutics Inc. Stay informed with Spero Therapeutics' Investor Relations updates. pdvm, juon, inhmb, jmfp, kyle4, iczl6, moasv, 3oggdi, 8fa5aq, 1kad,